Serum Omentin-1 Research Articles

Expression of Intelectin-1, also known as Omentin-1, is related to clinical phenotypes such as overweight, obesity, insulin resistance, and changes after bariatric surgery.

Intelectin-1 (ITLN1; also Omentin-1, OMNT1) is secreted by adipose tissue (AT) and plays an important role in glucose metabolism regulation, with links to obesity-associated diseases. ITLN1 activity so far has rarely been investigated using RNA-sequencing and in larger cohorts. We evaluated ITLN1 expression among three clinical cohorts of the Leipzig Obesity BioBank-a cross-sectional cohort comprising of 1480 people, a cohort of people with metabolically healthy or unhealthy obesity (31 insulin-sensitive, 42 insulin-resistant individuals with obesity), and a longitudinal two-step bariatric surgery cohort (n = 65). We hypothesized that AT ITLN1 expression is associated with serum omentin-1, clinical parameters associated with obesity, and with weight loss after bariatric surgery. We also investigated the correlation of AT ITLN1 expression with genes related to inflammatory response, lipid metabolism, obesity, and regulation of energy balance. Likewise, we inspected gene group expression and metabolic pathways associated with ITLN1 expression using gene set enrichment and gene correlation analysis. We show that ITLN1 expression differs in VAT and SAT, and should therefore be analyzed separately. Furthermore, ITLN1 expression increases with VAT tissue mass, but is negatively affected by AT tissue dysfunction among individuals with unhealthy obesity, corroborated by interplay with genes related to tissue inflammation. Gene set enrichment and gene correlation analysis of ITLN1 expression suggest that AT ITLN1 expression is related to local inflammatory processes in AT, but also in processes such as regulation of appetite, energy balance, and maintenance of body weight.

Evaluation of Serum Adipokine Levels in Girls With Central Precocious Puberty.

Adipose tissue has an important endocrine function by secreting a variety of hormones known as adipokines, such as Visfatin, Omentin-1 and Chemerin. On the other hand, these hormones are also secreted from places other than fatty tissues in the girl's genital system. The goal of this study was to demonstrate the secretory status of adipokines in patients with central precocious puberty (CPP) and their utility in the diagnosis of precocious puberty. A total of 105 patients were included in the study (53 in the CPP group and 52 in the control group). The following were used as the CPP diagnostic criteria; breast development, basal LH measurement higher than 0.3 IU/L, peak LH level ≥ 5 IU/L, peak LH/FSH ratio ≥ 0.66 (after 0.1 mg GnRH stimulation test) and a difference of at least 1 year between bone and chronological age. A statistically significant difference was detected between the groups in serum Omentin-1 and Chemerin levels, and no significant differences were detected between the groups in Visfatin values. The cut-off values for the diagnosis of CPP were calculated as ≤ 48.9 with 81% sensitivity and 54% specificity for Omentin-1, and as ≥ 417 with 85% sensitivity and 60% specificity for Chemerin. In our study, we found that Omentin-1 level decreased and Chemerin level increased in lean girls with CPP. More studies are needed to elucidate how adipokines play roles in explaining the onset of CPP, and whether they may be used as a reliable marker for the diagnosis of CPP.

Assessment of Serum Omentin-1 and Interleukin-6 in the Diagnosis of Early Stages of Diabetic Nephropathy: A Cross-Sectional Observational Study.

Introduction The pathogenesis of diabetic nephropathy highlights the progression of inflammation and fibrosis from tubular to glomerular damage during the early stages of kidney involvement in diabetic individuals. As urine albumin serves as a marker for glomerular function, its detection indicates a stage of diabetic nephropathy where the glomerulus is already compromised. Consequently, relying solely on urine albumin for diagnosis becomes questionable. In our pursuit of identifying innovative biomarkers for the early detection of diabetic nephropathy, this study was crafted to explore the relationship between chemokines, omentin-1, interleukin-6, and microalbuminuria. Materials and methods Our study cohort comprised 116 patients diagnosed with diabetes mellitus. In our study, participants were stratified into two groups based on their urine albumin levels: Group 1, characterized by urine albumin creatinine ratio <30 mg/gm and estimated glomerular filtration rate >90 ml/min, and Group 2, with urine albumin creatinine ratio ≥30 mg/gm and <300 mg/gm, and estimated glomerular filtration rate >60 ml/min and <90 ml/min.Serum creatinine, glycated hemoglobin (HbA1c), fasting blood sugar and post-prandial blood sugar, lipid profile, total protein, albumin, fasting insulin, omentin-1, and interleukin-6 were estimated. Result There was a significant difference in the medians of serum urea, creatinine, omentin-1, interleukin-6, urine albumin creatinine ratio, and estimated glomerular filtration rate levels in the two groups. There was no difference in fasting blood sugar, post-prandial blood sugar,HbA1c, serum lipids, fasting insulin, and homeostatic model assessment for insulin resistance. The receiver operating characteristic curve plotted for the newer biomarkers of diabetic nephropathy showed that there was a significant diagnostic utility in diabetic nephropathy detection of serum omentin (p=0.000), interleukin-6 (p=0.002), and interleukin-6: omentin-1 ratio (p=0.000), which correlated well with the routine test that is urine microalbumin estimation. Risk assessment demonstrated that type 2 diabetes mellitus patients with an interleukin-6: omentin-1 ratio ≥0.26 had significantly higher odds, with an odds ratio of 3.97, for developing diabetic nephropathy, which was statistically significant. Conversely, a ratio of ≤0.26 was associated with kidney protection among patients with type 2 diabetes mellitus. Conclusion Our findings revealed decreased levels of omentin-1 and increased levels of interleukin-6 in the group with diabetic nephropathy compared to those without diabetic nephropathy among patients with type 2 diabetes mellitus. Interleukin-6: omentin-1ratio of ≤0.26 was associated with kidney protection among patients with type 2 diabetes mellitus. Based on the results obtained from this study, we propose that measuring the serum interleukin-6: omentin-1 ratio in patients with type 2 diabetes mellitus may assist in identifying the early stages of diabetic nephropathy before the onset of microalbuminuria. Timely intervention in these patients predisposed to diabetic nephropathy can aid in better treatment outcomes in type 2 diabetes mellitus.

Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels

ObjectiveDiabetic foot ulcer (DFU) is a common and debilitating complication of diabetes that is associated with an increased risk of lower-limb amputation and a reduced life expectancy. Tibial cortex transverse transport (TTT) has become a newly alternative surgical method to facilitate ulcer healing and prevent lower limb amputation. Herein, we investigated the efficacy of TTT in treating DFU and changes of serum omentin-1 and irisin levels.MethodsThis study prospectively recruited 52 consecutive patients with DFU who were treated with TTT. The follow-up was performed weekly during the first 12 weeks postoperatively and every 3 months until 1 year after TTT. The serum levels of vascular endothelial growth factor (VEGF), omentin-1, and irisin in DFU patients undergoing TTT were determined by ELISA methods on the preoperative 1st day, postoperative 2nd week and 4th week.ResultsThe wound healing rate was 92.3% (48/52) at the 1-year follow-up. The visual analog scale (VAS) pain scores of patients showed a significant reduction at the 4th week after TTT (p < 0.001). The dorsal foot skin temperature, ankle brachial index, and dorsal foot blood flow of patients were significantly increased at the 4th week after TTT (p < 0.001). Results of ELISA methods showed the serum levels of VEGF, omentin-1, and irisin on the 2nd week and 4th week after TTT were notably elevated compared to the levels determined on the preoperative 1st day (p < 0.001). The serum levels of VEGF, omentin-1, and irisin on the 4th week after TTT were also significantly higher than the levels determined on the 2nd week after TTT (p < 0.001).ConclusionTTT could promote the wound healing and reduce the risk of lower limb amputation, demonstrating promising clinical benefits in the treatment of DFU. Increased expressions of serum proangiogenic factors including VEGF, omentin-1, and irisin were noted in the early stage after TTT, which may provide a new mechanism of TTT promoting wound heal.

Study of Serum Omentin-1 and IL-6 in Patients with Obesity, Hypertension and Hypertensive Nephropathy

Study of Serum Omentin-1 and IL-6 in Patients with Obesity, Hypertension and Hypertensive Nephropathy

Omentin associates with serum metabolite profiles indicating lower diabetes risk: KORA F4 Study

IntroductionCirculating omentin levels have been positively associated with insulin sensitivity. Although a role for adiponectin in this relationship has been suggested, underlying mechanisms remain elusive. In order to reveal the...

The Relationship between Omentin Gene (ITLN1) Variant rs190234680 and Serum Omentin levels in patients with Diabetic Foot

Diabetic foot is a common and serious complication of diabetes, characterized by neuropathy, ischemia, and infections which can lead to amputation of the affected limb. Omentin is a protein that is predominantly expressed in adipose tissue and has been implicated in insulin sensitivity and glucose metabolism. Low plasma omentin levels have been associated with several metabolic disorders, including T2DM. Objectives: Study objective were to assess the pattern of omentin-1 [ITLN1] single nucleotide gene polymorphism in diabetic foot patients compared to uncomplicated T2DM. It also sought to compare the serum omentin-1 levels between diabetic foot patients and those with uncomplicated Type 2 diabetes mellitus and determine the association between omentin levels and the clinical staging of diabetic foot patients. Methodology: In this cross-sectional analytical study, 130 participants of DF and T2DM were enrolled. Omentin (ITLN1) gene polymorphism(rs190234680) was determined by sequencing and serum omentin levels were estimated by ELISA. Result: A significant association was observed between the GG genotype (wild type) of the omentin (ITLN1) gene and diabetic foot, while no significant difference was found in serum omentin levels between cases and controls. The analysis did not provide clear evidence of a significant relationship between omentin levels in different grades of diabetic foot Conclusion:The study suggested that the GG genotype of omentin 1 gene may be an important risk factor in development of diabetic foot in patients with type 2 diabetes. However, there was no significant difference in serum omentin levels between different stages of diabetic foot.

Association between serum omentin-1 and mucosal disease activity in patients with ulcerative colitis.

Mucosal inflammation is a key feature of ulcerative colitis (UC), a chronic relapsing and remitting form of inflammatory bowel disease. Omentin-1, a newly discovered adipokine, is reported to have anti-inflammatory effects and has been found to be decreased in patients with inflammatory bowel disease. The aim of our study was to investigate the association between serum omentin-1 levels and mucosal disease activity in patients with UC. A total of 126 patients with UC and 77 healthy volunteers were enrolled in the study. Serum omentin-1 expression levels were measured using enzyme-linked immunosorbent assay to evaluate its potential for monitoring disease activity, including clinical and endoscopic activity. Serum omentin-1 levels were significantly lower in patients with UC compared to healthy controls (HC) (UC, 61.7 interquartile range: 51.5-72.6 versus healthy controls, 103.5 interquartile range: 48.3-156.2ng/ml; P < .001). Furthermore, serum omentin-1 levels were associated with both clinical and endoscopic activity in patients with UC. Notably, omentin-1 levels were significantly lower in patients who achieved mucosal healing. Receiver operating characteristic curves indicated that serum omentin-1 levels could potentially serve as an activity index for evaluating UC. These findings provide further insight into the association between omentin-1 and UC, suggesting that omentin-1 may be a useful biomarker for monitoring mucosal disease activity in patients with UC.

Оментин-1 и ишемическая болезнь сердца

Aim. The purpose of the review is to summarize the results of studies on the relationship between the level of omentin-1 and coronary artery disease (CAD). Key points. Adipose tissue is currently considered as an endocrine organ synthesizing biologically active factors known as adipocytokines, which may be involved in the pathogenesis of obesity-related metabolic and cardiovascular diseases, in particular, CAD. Omentin-1 is an adipocytokine that is predominantly secreted by visceral adipose tissue and plays an important role in the development of chronic inflammatory diseases, including CAD. Two isoforms of omentin are known: omentin-1 and omentin-2. Omentin-1 is the main circulating form of omentin. Its blood level in healthy people, according to different authors, varies from 1.61 to 815.3 ng/ml. A number of studies have found that the concentration of omentin-1 in the blood of women is higher than that of men, which may be due to sexual dimorphism of adipose tissue. The results of the studies indicate that the levels of omentin-1 circulating in the blood are associated with various metabolic risk factors. The review describes the main molecular mechanisms that determine these effects of omentin-1. A decrease in serum omentin-1 levels can be considered as an independent predictor of CAD and correlates with the severity and prognosis of this disease. A number of studies have established an association between the carriage of various variants of the omentin-1 (ITLN1) gene, CAD and obesity. The article analyzes the available data on the role of the level of omentin-1 in CAD, determined not only in the blood, but also in subcutaneous and visceral adipose tissue. The possible prospects for the use of various molecules capable of increasing the level of omentin-1 in the blood are analyzed. Conclusion. A decrease in the level of omentin-1 may be an independent predictor of CAD and is associated with the severity and progression of the disease. It is likely that omentin-1 can act as an alternative diagnostic tool to ensure optimal management of patients with CAD. Studies of the effect of omentin-1 on the prognosis in patients with various forms of CAD are largely ambiguous and therefore further, more comprehensive studies are needed. Keywords: coronary artery disease, acute coronary syndrome, omentin-1, adipokines, subcutaneous and visceral adipose tissue, omentin-1 gene (ITLN1).

Relationship between serum omentin-1 levels and nascent metabolic syndrome in Caucasian patients with obesity.

omentin-1 might present a potential role in metabolic syndrome (MS). The aim of our investigation was to evaluate the relationship between omentin-1 and nascent MS. we carried out a cross-sectional study in 606 obese subjects. Adiposity parameters, blood pressure, fasting blood glucose, insulin levels, insulin resistance (HOMA-IR), triglyceride and glucose index (TyG), lipid profile, C-reactive protein, omentin-1, and prevalence of nascent MS were determined. 307 subjects had MS (49.2 %) and 299 did not show MS (50.8 %). Subjects without MS have higher omentin-1 levels (delta: 78.0 ± 13.8 ng/ml; p = 0.01). A negative correlation was observed between omentin-1 and adiposity parameters, glucose, insulin, HOMA-IR, TyG index and triglycerides in both groups. And a positive correlation was observed with HDL-cholesterol. BMI (OR = 1.17, 95 % CI = 1.09-1.31; p = 0.02), HOMA-IR (OR = 5.21, 95 % CI = 1.69-21.11; p = 0.01) and omentin-1 (OR = 0.95, 95 % CI = 0.94-0.97; p = 0.02) remained in the final model as predictors of MS. The cut-off point according to the Youden index was 372.45 ng/ml of omentin-1, to predict MS. Caucasian patients with obesity had clearly lower serum omentin-1 levels in the presence of nascent MS. An inverse correlation was demonstrated with adiposity parameters, insulin resistance and triglycerides. And a direct correlation with HDL-cholesterol was reported.

Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C.

Patients with chronic hepatitis C virus (HCV) infection have increased serum omentin-1. Omentin-1 is an anti-inflammatory adipokine, and higher levels may be a direct effect of HCV infection. Successful elimination of HCV by direct acting antivirals almost normalized circulating levels of various molecules with a role in inflammation. To evaluate the effect of HCV infection on serum omentin-1, serum omentin-1 levels of HCV patients were measured before therapy and at 12 wk after therapy end. Associations of serum omentin-1 with parameters of inflammation and liver function were explored at both time points. Serum omentin-1 levels of patients with and without liver cirrhosis, which was defined by ultrasound or the fibrosis-4 (FIB-4) score, were compared. Serum omentin-1 levels were measured by enzyme-linked immunosorbent assay in 84 chronic HCV patients before therapy and at 12 wk after therapy end where sustained virological response 12 (SVR12) was achieved in all patients. Serum omentin-1 of 14 non-infected controls was measured in parallel. In patients with chronic HCV, serum omentin-1 levels were not related to viral load or viral genotype. HCV patients with liver steatosis and HCV patients with diabetes had serum omentin-1 levels comparable to patients not suffering from these conditions. Serum omentin-1 levels at SVR12 were similar in comparison to pretreatment levels. In addition, serum levels did not differ between HCV-infected patients and non-infected controls. Serum omentin-1 levels did not correlate with leukocyte count or C-reactive protein. Positive correlations of serum omentin-1 with bilirubin and the model for end-stage liver disease score (MELD) were detected before therapy and at SVR12 in the whole cohort. Bilirubin and the MELD score also positively correlated with serum omentin-1 levels in the subgroup of patients with ultrasound diagnosed liver cirrhosis before therapy. At SVR12, serum omentin-1 levels of patients with liver cirrhosis negatively correlated with albumin. Before therapy start, patients with high FIB-4 scores had increased serum omentin-1 in comparison to patients with a low score. Serum omentin-1 levels of patients with liver cirrhosis defined by ultrasound were increased at baseline and at SVR12. Present study showed that liver cirrhosis, but not HCV infection per se, is related to elevated serum omentin-1 levels.

Association of serum omentin levels with microvascular complications of type 2 diabetes mellitus: a systematic review and meta-analysis.

Type 2 diabetes mellitus (T2DM) is a chronic condition associated with various microvascular complications, including neuropathy, retinopathy, and nephropathy. Recent studies have suggested a potential association between serum omentin levels and the risk of developing microvascular complications in patients with T2DM. However, the existing evidence remains inconclusive. Therefore, we conducted a systematic review and meta-analysis to examine the association between serum omentin levels and microvascular complications in T2DM patients. A comprehensive search was conducted in PubMed, Scopus, and Google Scholar databases to retrieve relevant articles published up to May 2023. Observational studies investigating omentin levels association with microvascular complications in T2DM patients were included. Data was extracted and hence analyzed. A total of seven cross-sectional articles met the inclusion criteria, with a total population of 1587 participants. The meta-analysis revealed a significant association between serum omentin levels and microvascular complications in patients with T2DM. Serum omentin levels were lower in patients with microvascular complications than in those without complications (Mean difference, 95% confidence interval: -1.31 [-2.50, -0.13], I2 = 99.62%). This systematic review and meta-analysis provides evidence supporting an association between serum omentin levels and microvascular complications in patients with T2DM. The findings suggest that Omentin may be lower in T2DM patients with microvascular complications. Further research is warranted to elucidate the underlying mechanisms and explore the clinical implications of these findings. The online version contains supplementary material available at 10.1007/s40200-023-01359-2.

Estimation of Fibulin-1, Chemerin and Omentin-1 in Iraqi Women with Polycystic Ovary Syndrome-Associated Infertility

Background: Adipokines (fibulin-1, chemerin, and omentin-1) affect the hypothalamic-pituitary-gonadal axis and ovarian steroidogenesis. Adipocyte-secreted adipokines are dysregulated in females with polycystic ovarian syndrome (PCOS). Objective: To investigate the role of serum fibulin-1, chemerin, omentin-1, total cholesterol (TC), high-density lipoprotein (HDL), triglyceride (TG), progesterone (PROG), and prolactin (PRL) in PCOS and the development of infertility. Methods: 150 PCOS, infertile PCOS women and control women aged 20–40 years were enrolled in this observational study and divided into three groups: 40 women who were control, 60 women who had PCOS only, and 50 women who had infertility and PCOS. Analyses of fibulin-1, chemerin, omentin-1, lipid profile, PROG, and PRL were performed for all participants. Results: The results showed elevated levels of fibulin-1, chemerin, and PRL in both PCOS and infertile PCOS when compared with control, while omentine-1 and PROG decreased in both PCOS and infertile PCOS when compared with control. The levels of TC, HDL, and TG weren’t affected in PCOS alone, but in cases of infertility, TC and TG increased while HDL decreased. Conclusions: The increased level of fibulin-1 may be a new marker for PCOS and infertility. Chemerin shows a high level in both infertile PCOS and PCOS women, while omentin-1 shows a low level in both infertile PCOS and PCOS women.

Adipokines and Their Role in Heart Failure: A Literature Review.

Obesity is a major risk factor for heart failure (HF). The relationship between adipokines and HF has been implicated in many previous studies and reviews. However, this review article summarizes the basic role of major adipokines, such as apelin, adiponectin, chemerin, resistin, retinol-binding protein 4 (RBP4), vaspin, visfatin, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, nesfatin-1, progranulin, leptin, omentin-1, lipocalin-2, and follistatin-like 1 (FSTL1), in the pathogenesis of HF. Apelin is reduced in patients with HF and upregulated following favorable left ventricular (LV) remodeling. Higher levels of adiponectin have been found in patients with HF compared to in control patients. Also, high plasma chemerin levels are linked to a higher risk of HF. Serum resistin is related to the severity of HF and associated with a high risk for adverse cardiac events. Evidence indicates that RBP4 can contribute to inflammation and damage heart muscle cells, potentially leading to HF. Vaspin might stop the progression of cardiac degeneration, fibrosis, and HF according to experiments on rats with experimental isoproterenol-induced chronic HF. The serum concentrations of visfatin are significantly lower in patients with systolic HF. Leptin levels were found to be correlated with low LV mass and myocardial stiffness, both of which are significant risk factors for the development of HF with preserved ejection fraction (HFpEF). Measuring serum omentin-1 levels appears to be a novel prognostic indicator for risk stratification in HF patients. Increased expression of neutrophil gelatinase-associated lipocalin in both systemic circulation and myocardium in clinical and experimental HF suggests that innate immune responses may contribute to the development of HF. FSTL1 was elevated in patients with HF with reduced ejection fraction and associated with an increase in the size of the left ventricle of the heart. However, other adipokines, such as plasminogen activator inhibitor-1, monocyte chemotactic protein-1, nesfatin-1, and progranulin, have not yet been studied for HF.

Serum Omentin-1 Levels in Obese Adolescents with Vitamin D Deficiency: A Prospective Cross-sectional Study

Background: Vitamin D deficiency is common in obese adolescents. It modulates the release of omentin 1 from adipose tissue. We believe that both vitamin D and omentin 1 affect each other in adipose tissue via inflammation. Objectives: This study aimed to examine serum omentin-1 levels in obese adolescents with vitamin D (Vit D) deficiency. Methods: In this cross-sectional prospective study, 83 obese adolescents were included. Serum 25-hydroxy vitamin D (25(OH)D) concentrations, fasting glucose, and lipid profiles of obese adolescents were studied. At the same time, blood was drawn into a separate tube to study the omentin 1 level. Of the 83 obese cases, 45 with 25(OH)D concentrations below 20 ng/mL were considered as the study group, and 38 with 25(OH)D concentrations ≥ 20 ng/mL as the control group. Serum omentin-1 levels were evaluated and compared. Results: The average 25(OH)D value in the study and control groups was 17.14 ± 2.22 ng/mL and 45.29 ± 24.98 ng/mL, respectively. The average omentin-1 concentration of the control group was 262.5 ± 136.31 ng/mL, and the mean omentin-1 level of the study group was 113.23 ± 15.98 ng/mL. The mean omentin-1 concentrations of the study group were significantly lower compared to the control group (P = 0.0001). There was a significant and positive correlation between omentin-1 and 25(OH)D (r = 0.988, P = 0.0001). In univariate tests, linear regression analysis was carried out with 25(OH)D and omentin-1, and 25(OH)D displayed a significant positive correlation (P = 0.0001). The optimal cut-off point for the serum omentin-1 concentration was 135.01 ng/mL. No significant correlation was determined between omentin-1 and body mass index, lipid profile, glucose, and insulin variables (P &gt; 0.05). Conclusions: We showed significantly low concentrations of serum omentin-1 in obese adolescents with vitamin D deficiency. Serum omentin-1 can be employed as a biomarker in obese adolescents with vitamin D deficiency.

The potential value of some adipokines and cytokines as diagnostic biomarkers for prostate cancer

Abstract Background: The role of Adipokines and proinflammatory cytokines is said to be crucial in the development of prostate cancer. Vaspin, Chemerin, Omentin, Interleukins IL-1β, interleukin-8 (IL8), Colony-stimulating factor (GM-CSF) and CC chemokine ligand 18 (CCL18) have all been proven to take part in tumor growth and progression. Aim of the study: The study aimed to explore circulating novel adipocytokines, such as serum of Vaspin, Chemerin and Omentin levels in patients with prostate cancer and to determine the level of selected proinflammatory cytokines (CCL18, IL-8, IL1, and GM-CSF). Methods: Three groups were included in the current study: Group (1) :32 patients with metastatic prostate cancer who received chemotherapy, Group (2): 30 untreated patients with nonmetastatic prostate cancer, and Group (3): 30 healthy controls. ELISA technique was used to assess serum levels of Vaspin, Chemerin, Omentin, CCL18, IL-8, IL1, and GM-CSF). Results: The Prostate cancer group exhibited higher serum levels of Vaspin, Chemerin, Omentin, CCL18, IL-8, IL1, and GM-CSF compared to the control group. Chemotherapy-treated patients exhibited significantly increased levels of the pro-inflammatory cytokines (IL-8) and Adipokines (Vaspin and Omentin) and decreased levels of the pro-inflammatory cytokines (IL-1) and Adipokines (Chemerin). The correlation analysis showed a significant positive correlation of serum Chemerin with Vaspin (r = 0.957, p-value&lt;0.0001), IL-8 (r = 0.9475, p-value &lt; 0.0001) and IL-1β (r = 0.7771, p-value &lt; 0.0029). Omentin and GS-CSF levels showed a non-significant positive correlation with Chemerin level (r = 0.1259; p = 0.6967).) and (r = 0.4247; p = 0.1688), respectively. While significant negative correlation was found between (Chemerin) with CCL-18 (r = –0.7916, p = 0.0022), serum Vaspin was significantly and negatively correlated with the levels of CCL-18 (r = –0.9349, p &lt; 0.0001), whereas there was a significant positive correlation between Vaspin level with IL-8 (R=0.9995, p &lt;0.0001); IL-1β(r = 0.561, p = 0.0057). The data demonstrated that Vaspin was positively and non-significantly correlated with the level of GS-CSF (r = 0.1437, p =0.656); serum Omentin was significantly and negatively correlated with the levels of GS-CSF (r = –0.8447, p = 0.0005), and CCL-18 (r= –0.7058, p = 0.0103), whereas there was a non-significant positive correlation between Omentin level with IL-8 (r = 0.4364, p = 0.1561). The data demonstrated that Omentin was negatively and non-significantly correlated with the level of IL-1β (r= –0.5366, p =0.0786). Conclusions: This study indicated increased levels of serum Vaspin, Chemerin, Omentin, Interleukins IL-1β, interleukin-8 (IL8), Colony-stimulating factor (GM-CSF) and CC chemokine ligand 18 (CCL18) in patients with Prostate cancer. These findings suggest that the cytokines, and adipokines, whose levels were elevated in the chemotherapy-treated patients may be involved in the pathophysiology of prostate cancer. Vaspin, Chemerin and Omentin might play an important role in Prostate cancer progression through their association with Adipokines and proinflammatory cytokines. More studies are needed to investigate the possible role of Vaspin, Chemerin and Omentin as potential markers in the development of Prostate cancer.

Effect of high-intensity interval training on omentin-1 serum levels, gene expression, and insulin resistance in type 2 diabetic rats

Effect of high-intensity interval training on omentin-1 serum levels, gene expression, and insulin resistance in type 2 diabetic rats

The effect of exercise training on serum Omentin-1 levels, glycemic control and body composition in adults population: a systematic review and meta-analysis of randomized controlled trials

The effect of exercise training on serum Omentin-1 levels, glycemic control and body composition in adults population: a systematic review and meta-analysis of randomized controlled trials

In the Pursuit of Metabolic Markers of Systemic Sclerosis-Plasma Adiponectin and Omentin-1 in Monitoring the Course of the Disease.

Systemic sclerosis (SSc) is a connective tissue disease leading to cutaneous and visceral fibrosis. Pathological features of SSc include immune dysregulation, vasculopathy, and impaired angiogenesis. Adipokines act as cytokines and hormones and are involved in various pathological processes, including metabolic disorders, inflammation, vasculopathy, and fibrosis. This study aimed to determine the level of omentin-1 and adiponectin to evaluate their potential role in the pathogenesis of SSc. We assessed serum omentin-1 and adiponectin as well as metabolic parameters in 58 patients with SSc and 30 healthy controls. The follow-up was performed in SSc individuals. Omentin-1 levels were significantly higher in SSc individuals as compared to the controls. In post-hoc analysis, omentin-1 was higher in the group with disease duration ≥7 years than in the control group. A positive correlation was noted between disease duration and both adipokines and increased with longer disease duration. However, there were no correlations between selected adipokines and metabolic parameters. Enhanced omentin-1 levels and higher levels of omentin-1 in patients with longer disease duration may suggest that omentin-1 is involved in the pathomechanisms of SSc as its concentrations are not directly related to BMI, age, and insulin resistance.

Evaluation of Serum Omentin-1 Levels and Atherosclerotic Risk Factors in Patients with Prolactinoma

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)